Adipokines and risk of type 2 diabetes in older men

Diabetes Care

Volumn 30, Issue 5, 2007, Pages 1200-1205

  Wannamethee, S Goya ^a   Lowe, Gordon D O ^b   Rumley, Ann ^b   Cherry, Lynne ^b   Whincup, Peter H ^c   Sattar, Naveed ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN; INTERLEUKIN 6; LEPTIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FOLLOW UP; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RISK;

EID: 34247636175     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2416     Document Type: Article

References (36)

1. Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab 30:13-19, 2004
2. Trayhurn P, Wood IS: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 33: 1078-1081, 2005
3. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
4. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226-228, 2003
5. Daimin M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kata T: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population. Diabetes Care 26:2015-2020, 2003
6. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H: Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men. J Am Coll Cardiol 48:1369-1377, 2006
7. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matzusawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745-1751, 2003
8. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G: Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 53:2473-2478, 2004
9. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CDA, Nijpels G, Funahashi T, Matsuzawa Y, Shimoura I, Dekker JM: Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 29:2498-2503, 2006
10. Kanaya AM, Wassel Fyr C, Vittinghoff E, Harris TB, Park SW, Goodpaster BH, Tylavsky F, Cummings SR: Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166:350-356, 2006
11. McNeely MJ, Boyko EJ, Weigle DS, Shofer JB, Chessler SD, Leonnetti DL, Fujimoto WY: Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care 22:65-70, 1999
12. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G; the ARIC investigators: Leptin and incident type 2 diabetes: risk or protection? Diabetologia 9:2086-2096, 2006
13. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
14. Spranger J, Krpke A, Mohlig M, Hoffmann K, Bergman MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812- 817, 2003
15. Duncan BB, Schmidt MI, Pankow JS, Ballyntyne CM, Couper D, Vigo A Hoogeven R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 52: 1799-1805, 2003
16. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700, 2004
17. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C: Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/ KORA Augsburg Study, 1984-2002. Diabetes 54:2932-2938, 2005
18. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, Cozzolino D, Assaloni R, Merante D, Ceriello A, Giugliano D: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071-1076, 2006
19. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105, 2006
20. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG: British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. Br Med J (Clin Res Ed) 283:179-186, 1981
21. Wallace AM, McMahon AD, Packard CJ, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. Circulation 104:3052-3056, 2001
22. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L: Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105:1785-1790, 2002
23. Wannamethee SG, Shaper AG, Whincup PH: Overweight and obesity and the burden of disease and disability in elderly men. Int J Obes 28:1374-1382, 2004
24. Emberson J, Whincup PH, Walker M, Thomas M, Alberti KG: Biochemical measures in a population based study: the effect of fasting duration and time of day. Ann Clin Biochem 39:493-501, 2002
25. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578 -582, 1993
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
27. Walker M, Shaper AG, Lennon L, Whincup PH: Twenty year follow-up of a cohort study based in general practices in 24 British towns. J Publ Health Med 22:479-485, 2000
28. Perry IJ: Non-Insulin-Dependent Diabetes and Coronary Heart Disease in Middle-Aged British Men. PhD thesis. Royal Free and University College Medical School, London, 1995
29. Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005
30. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368(:1660-1672, 2006
31. Chessler SD, Fujimoto WY, Shofer JB, Boyko EJ, Weigle DS: Increased plasma leptin levels are associated with fat accumulation in Japanese Americans. Diabetes 47:239-243, 1998
32. Amar J, Perez L, Burcelin R, Chamontin B: Arteries, inflammation and insulin resistance. J Hypertens 24 (Suppl):S18 -S20, 2006
33. Kristiansen OP, Mandrup-Poulsen T: Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 (Suppl. 2):S114-S124, 2005
34. Yudkin JS, Eringa E, Stehouwer CD: "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365:1817-1820, 2005
35. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G: C-reactive protein and its role in metabolic syndrome: mendelian randomization study. Lancet 366:1954-1959, 2005
36. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817-2829, 2006